Anita Chawla, Ph.D., Vice President, Analysis Group
Dr. Chawla has extensive expertise using economic analyses to support the business objectives of biopharmaceutical and pharmaceutical companies, and other organizations in the health care sector. In her work she has assessed the value of a wide range of therapies to inform health care decision makers such as physicians, patients, payers, and policy makers. Throughout all phases of drug development, she has designed economic and outcomes research strategies for product development and commercialization objectives. Dr. Chawla has conducted research and published on a broad range of health economic issues, including treatment patterns and outcomes, economic burden of various illnesses, cost-effectiveness analysis in clinical trials, drug spending trends, and performance measures for prescription drug management. Her work has wide application in product development, commercial decision making, and health policy.
She is a member of the American Economic Association, American Society of Health Economists, and International Society for Pharmacoeconomics and Outcomes Research. She has served as a reviewer or referee for several journals, including Health Affairs, Health Services Research, Journal of the American Medical Association, and Journal of Business and Economic Statistics. Prior to joining Analysis Group, Dr. Chawla was Director of Health Economics & Outcomes Research at Genentech, Inc.
Dr. Chawla holds a Ph.D. in Economics from the University of Michigan and a B.A. in Economics and Political Science from Wellesley College.